Does the media prefer KRYS or TEVA?

In the previous week, Teva Pharmaceutical Industries had 26 more articles in the media than Krystal Biotech. MarketBeat recorded 31 mentions for Teva Pharmaceutical Industries and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.18 beat Teva Pharmaceutical Industries' score of 0.96 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 19 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KRYS or RVMD?

In the previous week, Revolution Medicines had 17 more articles in the media than Krystal Biotech. MarketBeat recorded 22 mentions for Revolution Medicines and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.18 beat Revolution Medicines' score of 0.29 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ONC or KRYS?

BeOne Medicines has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 5.67 $286.93M $4.47 61.77 Krystal Biotech $389.13M 25.77 $204.83M $7.48 45.48

Does the media favor ONC or KRYS?

In the previous week, BeOne Medicines had 7 more articles in the media than Krystal Biotech. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.18 beat BeOne Medicines' score of -0.18 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KRYS or MRNA more profitable?

Krystal Biotech has a net margin of 53.92% compared to Moderna's net margin of -143.55%. Krystal Biotech's return on equity of 19.25% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 53.92% 19.25% 17.62% Moderna -143.55% -26.64% -19.32%

Does the media refer more to KRYS or MRNA?

In the previous week, Moderna had 36 more articles in the media than Krystal Biotech. MarketBeat recorded 41 mentions for Moderna and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.18 beat Moderna's score of 0.40 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 16 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KRYS or BNTX?

In the previous week, Krystal Biotech had 2 more articles in the media than BioNTech. MarketBeat recorded 5 mentions for Krystal Biotech and 3 mentions for BioNTech. Krystal Biotech's average media sentiment score of 1.18 beat BioNTech's score of 0.85 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Krystal Biotech (KRYS) Competitors

$340.21 -3.22 (-0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$339.82 -0.38 (-0.11%)

As of 07:41 PM Eastern

Compare

KRYS vs. TEVA, RVMD, ONC, MRNA, and BNTX

Should you buy Krystal Biotech stock or one of its competitors? MarketBeat compares Krystal Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Krystal Biotech include Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), Moderna (MRNA), and BioNTech (BNTX). These companies are all part of the "pharmaceutical products" industry.

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Krystal Biotech (NASDAQ:KRYS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Teva Pharmaceutical Industries has higher revenue and earnings than Krystal Biotech. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.77	$204.83M	$7.48	45.48
Teva Pharmaceutical Industries	$17.26B	2.21	$1.41B	$1.33	24.93

Krystal Biotech has a net margin of 53.92% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Krystal Biotech presently has a consensus target price of $340.56, suggesting a potential upside of 0.10%. Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 25.99%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Teva Pharmaceutical Industries had 26 more articles in the media than Krystal Biotech. MarketBeat recorded 31 mentions for Teva Pharmaceutical Industries and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.18 beat Teva Pharmaceutical Industries' score of 0.96 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	19 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Teva Pharmaceutical Industries on 10 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Revolution Medicines?

Krystal Biotech (NASDAQ:KRYS) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Revolution Medicines had 17 more articles in the media than Krystal Biotech. MarketBeat recorded 22 mentions for Revolution Medicines and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.18 beat Revolution Medicines' score of 0.29 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has a net margin of 53.92% compared to Revolution Medicines' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Revolution Medicines	N/A	-83.22%	-59.06%

Krystal Biotech currently has a consensus target price of $340.56, suggesting a potential upside of 0.10%. Revolution Medicines has a consensus target price of $123.72, suggesting a potential downside of 27.01%. Given Krystal Biotech's higher probable upside, equities research analysts clearly believe Krystal Biotech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.77	$204.83M	$7.48	45.48
Revolution Medicines	$11.58M	3,112.07	-$1.13B	-$7.07	N/A

Summary

Krystal Biotech beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Krystal Biotech (NASDAQ:KRYS) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

In the previous week, BeOne Medicines had 7 more articles in the media than Krystal Biotech. MarketBeat recorded 12 mentions for BeOne Medicines and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.18 beat BeOne Medicines' score of -0.18 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

BeOne Medicines currently has a consensus price target of $390.00, indicating a potential upside of 41.24%. Krystal Biotech has a consensus price target of $340.56, indicating a potential upside of 0.10%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities analysts clearly believe BeOne Medicines is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has a net margin of 53.92% compared to BeOne Medicines' net margin of 8.94%. Krystal Biotech's return on equity of 19.25% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Krystal Biotech	53.92%	19.25%	17.62%

BeOne Medicines has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.67	$286.93M	$4.47	61.77
Krystal Biotech	$389.13M	25.77	$204.83M	$7.48	45.48

Summary

Krystal Biotech beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Moderna?

Krystal Biotech (NASDAQ:KRYS) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Krystal Biotech has a net margin of 53.92% compared to Moderna's net margin of -143.55%. Krystal Biotech's return on equity of 19.25% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Moderna	-143.55%	-26.64%	-19.32%

Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Krystal Biotech has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.77	$204.83M	$7.48	45.48
Moderna	$1.94B	12.45	-$2.82B	-$8.15	N/A

In the previous week, Moderna had 36 more articles in the media than Krystal Biotech. MarketBeat recorded 41 mentions for Moderna and 5 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.18 beat Moderna's score of 0.40 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	16 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech presently has a consensus price target of $340.56, indicating a potential upside of 0.10%. Moderna has a consensus price target of $36.60, indicating a potential downside of 40.00%. Given Krystal Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe Krystal Biotech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

Krystal Biotech beats Moderna on 13 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to BioNTech?

Krystal Biotech (NASDAQ:KRYS) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Krystal Biotech presently has a consensus price target of $340.56, suggesting a potential upside of 0.10%. BioNTech has a consensus price target of $129.56, suggesting a potential upside of 42.97%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Krystal Biotech has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	25.77	$204.83M	$7.48	45.48
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A

In the previous week, Krystal Biotech had 2 more articles in the media than BioNTech. MarketBeat recorded 5 mentions for Krystal Biotech and 3 mentions for BioNTech. Krystal Biotech's average media sentiment score of 1.18 beat BioNTech's score of 0.85 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Krystal Biotech has a net margin of 53.92% compared to BioNTech's net margin of -44.39%. Krystal Biotech's return on equity of 19.25% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

Krystal Biotech beats BioNTech on 11 of the 17 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.12B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	45.48	19.75	24.92	23.98
Price / Sales	25.77	331.30	528.51	109.04
Price / Cash	47.11	128.56	44.82	54.51
Price / Book	8.09	8.29	10.79	6.50
Net Income	$204.83M	$23.85M	$3.56B	$336.88M
7 Day Performance	5.21%	5.21%	1.67%	-0.22%
1 Month Performance	13.61%	2.19%	0.43%	0.77%
1 Year Performance	146.67%	60.99%	32.84%	31.57%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	2.4903 of 5 stars	$340.21 -0.9%	$340.56 +0.1%	+159.3%	$10.12B	$389.13M	45.48	210	Positive News Analyst Downgrade
TEVA Teva Pharmaceutical Industries	4.5657 of 5 stars	$32.25 +2.4%	$41.78 +29.6%	+90.0%	$36.20B	$17.35B	24.24	33,950	Positive News Options Volume
RVMD Revolution Medicines	1.6579 of 5 stars	$165.81 +1.7%	$123.72 -25.4%	+318.1%	$34.65B	$11.58M	N/A	250
ONC BeOne Medicines	4.147 of 5 stars	$271.80 +0.6%	$390.00 +43.5%	+10.0%	$29.64B	$5.34B	60.81	12,000	Analyst Downgrade
MRNA Moderna	1.2411 of 5 stars	$59.35 -7.2%	$36.60 -38.3%	+129.2%	$25.38B	$1.94B	N/A	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. TEVA, RVMD, ONC, MRNA, and BNTX

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Summary

How does Krystal Biotech compare to Revolution Medicines?

Summary

How does Krystal Biotech compare to BeOne Medicines?

Summary

How does Krystal Biotech compare to Moderna?

Summary

How does Krystal Biotech compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. TEVA, RVMD, ONC, MRNA, and BNTX

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Which has higher valuation and earnings, KRYS or TEVA?

Is KRYS or TEVA more profitable?

Do analysts recommend KRYS or TEVA?

Which has more volatility and risk, KRYS or TEVA?

Do institutionals and insiders hold more shares of KRYS or TEVA?

Does the media prefer KRYS or TEVA?

Summary

How does Krystal Biotech compare to Revolution Medicines?

Does the media refer more to KRYS or RVMD?

Is KRYS or RVMD more profitable?

Do analysts rate KRYS or RVMD?

Which has more risk & volatility, KRYS or RVMD?

Do insiders & institutionals hold more shares of KRYS or RVMD?

Which has preferable valuation and earnings, KRYS or RVMD?

Summary

How does Krystal Biotech compare to BeOne Medicines?

Does the media favor ONC or KRYS?

Do insiders and institutionals have more ownership in ONC or KRYS?

Which has more risk and volatility, ONC or KRYS?

Do analysts rate ONC or KRYS?

Is ONC or KRYS more profitable?

Which has preferable valuation and earnings, ONC or KRYS?

Summary

How does Krystal Biotech compare to Moderna?

Is KRYS or MRNA more profitable?

Which has more risk and volatility, KRYS or MRNA?

Do insiders & institutionals believe in KRYS or MRNA?

Which has better valuation & earnings, KRYS or MRNA?

Does the media refer more to KRYS or MRNA?

Do analysts prefer KRYS or MRNA?

Summary

How does Krystal Biotech compare to BioNTech?

Which has more volatility & risk, KRYS or BNTX?

Do analysts prefer KRYS or BNTX?

Which has stronger earnings and valuation, KRYS or BNTX?

Does the media prefer KRYS or BNTX?

Do insiders & institutionals have more ownership in KRYS or BNTX?

Is KRYS or BNTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools